These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 33294721)

  • 21. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.
    Mittal L; Kumari A; Srivastava M; Singh M; Asthana S
    J Biomol Struct Dyn; 2021 Jul; 39(10):3662-3680. PubMed ID: 32396769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
    Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
    J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual Screening of
    Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
    Onyango H; Odhiambo P; Angwenyi D; Okoth P
    J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
    Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
    J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing of pyrazolotriazine derivatives as potential anti-SARS-CoV-2 agents: in vitro and in silico studies.
    Oudah KH; Najm MAA; Barghash RF; Kutkat O; GabAllah M; Albohy A; Abouzid KAM
    BMC Chem; 2024 Jul; 18(1):132. PubMed ID: 39014447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
    Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
    Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
    Marshall TG; Lee RE; Marshall FE
    Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
    Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
    Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening of potential inhibitors targeting the main protease structure of SARS-CoV-2
    Yang X; Xing X; Liu Y; Zheng Y
    Front Pharmacol; 2022; 13():962863. PubMed ID: 36278156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
    Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
    J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
    Ahmed MZ; Zia Q; Haque A; Alqahtani AS; Almarfadi OM; Banawas S; Alqahtani MS; Ameta KL; Haque S
    J Infect Public Health; 2021 May; 14(5):611-619. PubMed ID: 33866129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and
    Mahmoud A; Mostafa A; Al-Karmalawy AA; Zidan A; Abulkhair HS; Mahmoud SH; Shehata M; Elhefnawi MM; Ali MA
    Heliyon; 2021 Sep; 7(9):e07962. PubMed ID: 34518806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
    Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
    J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
    Rahman MM; Saha T; Islam KJ; Suman RH; Biswas S; Rahat EU; Hossen MR; Islam R; Hossain MN; Mamun AA; Khan M; Ali MA; Halim MA
    J Biomol Struct Dyn; 2021 Oct; 39(16):6231-6241. PubMed ID: 32692306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.